• Small Molecules
      • Discovery
        Development
        Manufacturing
    • Biologics
      • Discovery
        Development & Manufacturing
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery

      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

        Know More
        Know More
    • Industries
    • Emerging Biopharma

      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

        Know More
        Know More
    • Dedicated Centers

      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

        Know More
        Know More
    • Center for Advanced Protein Studies (CAPS)

      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

        Know More
        Know More
    • Investors
      Corporate Governance
  • Careers
Syngene wins CDMO Leadership Award 2025

Adjudged winner in the Biologics category by Outsourced Pharma and Life Science Connect publications.

Syngene concludes acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc

New site to increase Syngene’s total single-use bioreactor capacity to 50,000L for large molecules

Read Press Release
India’s CRDMO growth potential at $22-$25B by 2035: BCG-IPSO Report

Syngene collaborates with 11 CRDMOs to form IPSO; elevate India’s position in the global pharma value-chain

Read Press Release
Manufacturing the drug substance for Zoetis’ first-in-class mAb osteoarthritis drug
Read Case Study
Syngene wins CDMO Leadership Award 2025

Adjudged winner in the Biologics category by Outsourced Pharma and Life Science Connect publications.

Syngene concludes acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc.

New site to increase Syngene’s total single-use bioreactor capacity to 50,000L for large molecules

Read Press Release
India’s CRDMO growth potential at $22-$25B by 2035: BCG-IPSO Report

Syngene collaborates with 11 CRDMOs to form IPSO; elevate India’s position in the global pharma value-chain

Read Press Release
Manufacturing the drug substance for Zoetis’ first-in-class mAb osteoarthritis drug
Read Case Study

Who we are

We are an innovation-led contract research, development and manufacturing organization offering integrated scientific services from early discovery to commercial supply.

More
More

What we do

We offer clients a customized end-to-end solution to fulfil their R&D and manufacturing requirements. Our approach enables us to forge client relationships that move beyond the traditional service outsourcing model into true end-to-end collaborations.

Discovery

Our Discovery Services span the entire spectrum of early stage research from target …

More
More

Development

Our Development Services encompass activities from pre-clinical to clinical trials…

More
More

Manufacturing

Our Manufacturing services include cGMP-compliant facilities for clinical supplies, registration batches…

More
More

Dedicated Centers

Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support…

More
More

InstaVisit – Visit Syngene virtually

Syngene InstaVisit is an interactive virtual experience designed to give you a 360 degree view of Syngene’s world-class facilities and capabilities. The platform allows you to change your perspective, look around and zoom in as we take you on a guided tour of Syngene’s labs.

View Now
View Now
Visit Syngene virtually with a 360 degree view of Syngene’s world-class facilities and capabilities
0 +

Active Clients

0

Collaborations with top 20 Pharma/Biotech companies

5200

Scientists

0

Mn sq. ft. of R&D and manufacturing infrastructure

0 +

Patents 

Latest News

View all
View all

Antibody-drug conjugates are a significant evolution in drug development landscape: Dr. Kenneth Barr

More
News
13th Apr, 2025

PROTACs: Current Landscape and Their Significance in Drug Discovery

More
News
27th Mar, 2025

Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc.

More
Press Release
19th Mar, 2025

Insights

View all
View all

Reducing variability in gene expression: Bottlenecks and Solutions

Explore challenges in reducing the variability in gene expression in traditional cell line development (CLD) and the power of the transposon system to address these inefficiencies.
More

Quantifying a biomarker in mice brain for treating mood and anxiety disorders

A robust LC-MS-based quantitative method developed at Syngene to measure biomarker 2-AG in mice brain tissues for treating mood and anxiety disorders.
More

Risk assessment strategy for nitrosamine drug substance-related impurities

The potential causes of nitrosamine drug substance-related impurities and Syngene’s strategic framework for identification and management of these impurities to meet regulatory guidelines for product safety.
More

Upcoming events

View all
View all

World Vaccine Congress USA 2025

April 21st-24th
Washington

Festival of Biologics USA 2025

April 23rd-24th
San Diego

AACR 2025

April 25th-30th
Chicago

International Conference on Biologics & Biosimilars Italy (Keynoteconnect)

April 28th
Rome

AAPS – NBC 2025

May 4th-7th
Boston

Swiss Biotech Day 2025

May 5th-6th
Basel

Corporate Social Responsibility

To strive towards developing and sustaining healthy and empowered communities by improving the quality of life.
More
More

Governance

Behind consistent growth is good governance

More
More

Careers

Discover a world of opportunities

More
More

Annual Reports

Touching a billon lives through innnovation

More
More

Sign-up for our newsletter

© 2025. Syngene International Limited

Linkedin-in Youtube Facebook-f

Quick links

Business

Get in touch

Other links
Linkedin-in Youtube Facebook-f

© 2025. Syngene International Limited

To view or email, Please share your details view

Download PDF
Download PDF

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details